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Transcellular diffusion across the absorptive
epithelial cells (enterocytes) of the small intes-
tine is the main route of absorption for most
orally administered drugs. The process bywhich
lipophilic compounds transverse the aqueous
environment of the cytoplasm, however, re-
mains poorly defined. In the present study, we
have identified a structurally diverse group of
lipophilic drugs that display low micromolar
binding affinities for a cytosolic lipid-binding
protein—intestinal fatty acid-binding protein
(I-FABP). Binding to I-FABP significantly en-
hanced the transport of lipophilic drug mole-
culesacrossamodelmembrane, and thedegree
of transport enhancement was related to both
drug lipophilicity and I-FABP binding affinity.
These data suggest that intracellular lipid-
binding proteins such as I-FABP may enhance
the membrane transport of lipophilic xenobiotics
and facilitate drug access to the enterocyte
cytoplasm and cytoplasmic organelles.
INTRODUCTION
Intracellular lipid-binding proteins (iLBPs) are a diverse
family of low-molecular weight (12–15 kDa) cytosolic pro-
teins [1, 2]. The fatty acid-binding protein (FABP) subfam-
ily of iLBPs is of particular interest since, in many cells,
FABPs are the most abundant proteins and may consti-
tute as much as 3%–6% of the cytosolic protein [1, 3].
While FABPs show distinctive tissue and cellular distribu-
tion patterns, it is not uncommon for FABPs to be
expressed in multiple tissue types, and in the enterocyte
both intestinal (I)-FABP and liver (L)-FABP are present in
relatively high concentrations [3, 4].
Cytosolic FABPs display a common tertiary structure.
Their consensus topology consists of two b sheets, which
form a ‘‘clam-like’’ structure that encloses a large solvated
cavity and is capped by a helix-turn-helix motif [2]. It isChemistry & Biology 14,thought that the a-helical region acts as a ‘‘dynamic
portal,’’ which opens to allow ligand entry to the binding
cavity and then interacts with the bound ligand to cap
the cavity opening [5–7]. All FABPs bind long-chain fatty
acids (FAs); however, the stoichiometry of binding varies
among the different members of the family. I-FABP, for
example, binds FAs in a 1:1 stoichiometric ratio, while
L-FABP binds two FAs in what appears to be an interde-
pendent manner [5–8].
Despite extensive study, the precise physiological role
of FABPs remains enigmatic. While a role in the intracellu-
lar trafficking of long-chain FAs is clear [1, 2, 9, 10], FABPs
also bind non-FA ligands, including heme, eicosanoids,
and xenobiotics [9, 11, 12], albeit with a markedly lower
affinity. The biological significance of these lower-affinity
binding interactions is not well understood. However,
the concentration of FABPs in the enterocyte far exceeds
the concentration of free FAs [1, 3], and significant quan-
tities of FABP are likely to be available for binding these
other ligands, even in the presence of endogenous FAs.
For orally administered drugs, passage across the
enterocyte is a potential barrier to effective absorption
[13, 14]. Historically, attention has focused on the interac-
tion of drugs with membrane transporters located on ei-
ther the apical or basolateral membrane of the enterocyte
[15]. In contrast, drug transport from the apical enterocyte
membrane into the cytoplasm, diffusion across the cyto-
plasm, and subsequent access to the basolateral mem-
brane have been almost entirely neglected. In this respect,
transport across the primarily aqueous cytoplasm is
expected to be most problematic for poorly water-soluble,
lipophilic molecules. In a recent report, evidence for the
binding of a limited number of non-FA lipophilic drugs to
I-FABP was established, suggesting that I-FABP could
serve as a water-soluble drug carrier in the enterocyte
[11]. In the present communication, those findings have
been expanded to provide definitive data describing the
binding of several homologous series of drug molecules
to I-FABP. From these data, indications of structure-bind-
ing relationships between drug molecules and I-FABP
have been inferred. Data reflecting the likely passive trans-
port processes at the apical and basolateral membrane
domains of the enterocyte have been generated by using453–465, April 2007 ª2007 Elsevier Ltd All rights reserved 453
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Intestinal Fatty Acid-Binding Protein and Drug AbsorptionTable 1. Binding Affinity of I-FABP for Different Series of Structurally Related Compounds as Determined
Fluorometrically by Displacement of ANS
Ligand
Ki
a (mM)
(Mean ± SD, n = 3)
Ki
b (mM)
(Mean ± SD, n = 3) Log DpH 7.4
Fatty Acids
Myristic acid (14:0) 0.041 ± 0.002 0.061 ± 0.004 3.48
Palmitic acid (16:0) 0.024 ± 0.001 0.038 ± 0.001 4.54
Fenamates
Tolfenamic acid 2.8 ± 0.7 7.2 ± 0.9 2.32
Flufenamic acid 3.7 ± 0.8 10.9 ± 1.8 2.03
Meclofenamic acid 8.9 ± 2.0 21 ± 5.3 2.27
Mefenamic acid 63 ± 10 110 ± 18 1.77
Diclofenac 150 ± 9.6 520 ± 11 0.11
Propionic Acid Derivatives
Fenoprofen 14 ± 0.5 64 ± 4.1 0.69
R-Flurbiprofen 15 ± 2.8 48 ± 3.1 0.92
(R/S)-Flurbiprofen 20 ± 2.3 70 ± 11 0.92
Ketoprofen 24 ± 3.0 74 ± 3.4 0.31
S-Flurbiprofen 26 ± 1.1 67 ± 2.2 0.92
R-Ibuprofen 32 ± 4.2 64 ± 1.5 0.77
(S)-(-)-Naproxen 56 ± 4.2 180 ± 6.8 0.03
(R/S)-Ibuprofen 58 ± 8.4 100 ± 8.8 0.77
S-Ibuprofen 84 ± 2.5 150 ± 1.4 0.77
Indoprofen 130 ± 1.8 190 ± 0.3 1.23
Nabumetone NBc NBc 2.82
Fibrates
Fenofibric acid 1.0 ± 0.2 3.7 ± 0.1 0.04
Ciprofibrate 24 ± 1.1 72 ± 3.5 1.28
Bezafibrate 33 ± 0.7 100 ± 4.4 0.17
Clofibric acid 52 ± 1.8 110 ± 9.4 1.13
Naphthalene Derivatives
bisANS 2.0 ± 0.5 5.6 ± 0.7 2.19
ANS 3.2 ± 0.3 7.3 ± 0.2 1.27
TNS 45 ± 10 130 ± 21 0.81
Bridged Bi-Phenyl Compounds
Benzyl salicylate NBc NBc 3.93
Pyrilamine NBc NBc 1.64
Phenytoin NBc NBc 2.47
Bifenox NBc NBc 5.79
Verapamil NBc NBc 3.4
Mepronil NBc NBc 4.12
N-Phenyl-2,3-xylidine NBc NBc 3.89
Other Mono-Carboxylic Acid Derivatives
Acifluorfen 4.2 ± 1.2 8.9 ± 2.1 1.90
2-Naphthoxyacetic acid 7.2 ± 1.9 14 ± 3.6 1.28454 Chemistry & Biology 14, 453–465, April 2007 ª2007 Elsevier Ltd All rights reserved
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Ligand
Ki
a (mM)
(Mean ± SD, n = 3)
Ki
b (mM)
(Mean ± SD, n = 3) Log DpH 7.4
1-Naphthaleneacetic acid 32 ± 5.7 60 ± 8.7 0.33
Benzilic acid 110 ± 14 200 ± 24 1.07
Jasmonic acid 140 ± 21 350 ± 30 1.19
Valproate 240 ± 23 470 ± 22 0.15
Asprin 300 ± 11 460 ± 18 2.51
Nalidixic acid NBc NBc 2.86
Indole Acids
Indole-3-butyric acid 72 ± 12 170 ± 16 0.21
3-Indoleacetic acid 93 ± 16 200 ± 21 1.21
Heteroaryl Acetic Acid Derivatives
Tolmetin 1300 ± 80 2200 ± 94 1.36
Ketorolac 1700 ± 110 2300 ± 120 1.90
Steroids
Progesterone 20 ± 4.6 32 ± 5.3 4.04
Prednisolone 95 ± 9.4 113 ± 10 1.69
Dexamethasone 1100 ± 109 1200 ± 130 2.06
Cortexolone 1600 ± 89 1900 ± 112 2.74
Benzodiazepines
Diazepam 2000 ± 87 2200 ± 110 2.96
Nitrazepam 2000 ± 95 2300 ± 96 2.84
Lorazepam 2100 ± 92 2500 ± 105 2.48
a 20 mM Tris-HCl (pH 8.0) buffer.
b 50 mM Tris-HCl (pH 8.0), 150 mM NaCl buffer.
c NB, no binding detected.artificial phospholipid membranes, and functional infor-
mation describing the effects of a FABP on transmem-
brane drug transport is presented. Together, these data
suggest a possible role for iLBPs in both facilitating drug
transport across the enterocyte and regulating intracellu-
lar drug disposition.
RESULTS
Binding of I-FABP for Selected Lipophilic Drugs
The binding affinity of I-FABP for several series of lipo-
philic drugs is documented in Table 1 (and Figure S1;
see the Supplemental Data available with this article on-
line). The apparent octanol-water partition coefficient for
each drug at pH 7.4 (log D7.4) is shown as a measure of lip-
ophilicity. In general, compounds containing a terminal
carboxylate and an extended hydrophobic moiety
showed the greatest binding affinity for I-FABP. The im-
portance of the carboxylate is highlighted by comparing
compounds, such as nabumetone (no significant binding)
and naproxen (Ki = 56 mM), that differ principally in the
presence or absence of the carboxylate functionality. An
increase in Ki was also observed under high-salt bufferChemistry & Biology 14conditions, suggesting that ionic interactions are a sig-
nificant factor in drug-I-FABP binding. The carboxylate
group, however, is not an absolute requirement for bind-
ing, as demonstrated by certain steroids that show rea-
sonable (albeit generally lower) binding affinities. Further-
more, a carboxylate group per se is not sufficient for
binding, as several carboxylic acids were demonstrated
not to bind.
The hydrophobic moiety is also important in determin-
ing binding affinity. For example, across the fenamates,
propionic acid derivatives, and fibrates, there are com-
pounds that differ primarily in the nature of the hydropho-
bic moiety, but that have binding affinities that differ by
more than an order of magnitude. In general, compounds
of similar size to the native FA ligands have the highest af-
finity. Compounds with shorter lipophilic chains (e.g., as-
pirin) or more bulky attachments (e.g., indoprofen) gener-
ally display lower affinities. Compounds in which the
carboxylate is either absent or not at the terminus also dis-
play generally lower affinities. An exception to this trend is
the naphthalene sulfonic acid series. However, we have
previously shown that the binding mode of 1-anilino-8-
naphthalene sulfonic acid (ANS) is somewhat different, 453–465, April 2007 ª2007 Elsevier Ltd All rights reserved 455
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previously observed for ANS and adipocyte lipid-binding
protein (ALBP) [16].
Ligand-Induced Chemical-Shift Changes in I-FABP
To examine the binding of a range of drugs to I-FABP, a se-
ries of NMR chemical-shift perturbation experiments was
undertaken. It has previously been shown that ligand bind-
ing results in perturbation of a large proportion of the
1H-15N crosspeaks in spectra of I-FABP [11, 17]. This is
also the case in the current study, in which titration of
each of the drugs resulted in perturbation of the majority
of 1H-15N resonances (Figure S2). As such, precise inter-
pretation of 1H-15N chemical-shift perturbations is prob-
lematic. In contrast, measurements of 13C chemical-shift
perturbations typically provide a more precise description
of the binding site [18]. This has been demonstrated for
I-FABP binding to its endogenous ligand, FA [17]; binding
to palmitate results in significant perturbations in 13Ca and
13Cb chemical shifts for residues that are located at the
binding interface (Figure 1).
Palmitate binds to I-FABP with the carboxylate head
group buried within the cavity, where it forms a salt bridge
with Arg106 and H bonds with both Arg106 and Trp82 [19].
The methylene tail of the FA binds in a bent conformation
within a concave crevice lined with aromatic and hydro-
phobic amino acids. The methyl terminus of the FA acyl
chain makes van der Waals contacts with aromatic ‘‘cap-
ping’’ residues within the portal. A 13Ca and
13Cb chemical-
shift perturbation map for palmitate binding to I-FABP,
based on the published data [17], demonstrates that the
residues undergoing significant chemical-shift perturba-
tions are located almost exclusively at the binding inter-
face. In the present study, we have assigned 13Ca and
13Cb chemical shifts for apo-I-FABP and for I-FABP com-
plexes with fenofibric acid, clofibric acid, and tolfenamic
acid. (Deposited at BioMagResBank with accession num-
bers 15082, 7356, 7357, and 7355.) The results of the
chemical-shift perturbation experiments are presented in
Figure 1, in which the residues undergoing significant per-
turbations are mapped onto the crystallographic structure
of I-FABP. Also shown are the highest-scoring poses for
each of the ligands docked into I-FABP.
In the docking solution for fenofibric acid, the terminal
carboxylate interacts with residues at the bottom of the
I-FABP binding cavity in a similar manner to FAs. The re-
mainder of the fenofibric acid interacts with residues in
the hydrophobic crevice and makes contacts with portal
residues. This mode of binding is supported by the chem-
ical-shift perturbation data. In contrast, both the docking
solution and chemical-shift mapping data for clofibric
acid and tolfenamic acid suggest a mode of binding dis-
tinct from that of FAs. Thus, for clofibric acid, the residues
that undergo the most significant perturbations are clus-
tered at the bottom of the cavity, with few changes being
observed in either the hydrophobic crevice or the portal
region. This supports the docking solution, which shows
the terminal carboxylate of clofibric acid positioned at
the bottom of the cavity. From this position, the smaller456 Chemistry & Biology 14, 453–465, April 2007 ª2007 Elseviclofibric acid does not extend to the hydrophobic crevice
or portal, and this is reflected in the lack of observed
chemical-shift perturbations in these regions. For tolfe-
namic acid, the carboxylate functionality is attached di-
rectly to the benzene ring. As such, while the carboxylate
is still capable of interacting with Arg106, the steric bulk
of the benzene ring prevents the carboxylate from pene-
trating deeply into the I-FABP binding cavity. For FAs,
fenofibric acid, and clofibric acid, the carboxylate inter-
acts with Arg106 in a bidentate fashion, such that both
carboxylate oxygens interact with the Arg106 guanidinium
group. With tolfenamic acid, the interaction is monoden-
tate, and only one of the carboxylate oxygens interacts
with Arg106. This is reflected in the lack of chemical-shift
perturbations observed at the bottom of the cavity for
tolfenamic acid.
Impact of Drug-FABP Binding on Membrane
Transport
To examine the hypothesis that iLBPs facilitate transport
across the apical absorptive membrane of the enterocyte
and into the cytosol, a parallel artificial membrane perme-
ability assay (PAMPA) has been utilized to model absorp-
tion events at the apical and basolateral membrane
domains. The PAMPA system consists of a multilamelar
membrane supported on a filter disc that separates two
aqueous domains (vide infra). The PAMPA model was val-
idated by assessment of the permeability of two reference
compounds (caffeine and mannitol) that do not bind
I-FABP. The data obtained were consistent with the litera-
ture [14] and did not change regardless of the presence or
absence of I-FABP (Tables 2 and 3).
The experimental PAMPA data were obtained by using
protocols designed to reflect uptake across the apical
membrane and transport across the basolateral mem-
brane. To examine uptake across the apical membrane,
transport buffer was used in the donor chamber, and the
impact of either buffer or 0.33 mM I-FABP in the accep-
tor chamber was evaluated. The I-FABP concentration
(0.33 mM) was chosen to resemble the cytosolic level of
I-FABP in enterocytes [1, 3]. Transport across the basolat-
eral membrane was examined by employing I-FABP in
the donor (cytoplasmic) chamber and either buffer or
0.66 mM HSA in the acceptor chamber. The concentration
of HSA in the acceptor chamber was chosen to reflect the
albumin concentration in plasma [20]. In this way, the
model PAMPA system provides for experimental flexibility
that is not evident during examination of transport across,
for example, a cell monolayer, where transport events
across apical and basolateral membranes are necessarily
aggregated.
In the experiments designed to reflect events across the
apical membrane, the rate of membrane uptake was ob-
tained from the rates of drug loss from the donor solution
(Figure 2, left-hand panel). Apparent permeability coeffi-
cients generated from disappearance plots revealed little
difference in the rate of uptake of the most lipophilic
probes, i.e., oleic acid (log D7.4 = 3.48), progesterone
(log D7.4 = 4.04), and diazepam (log D7.4 = 2.96) (Table 2).er Ltd All rights reserved
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Intestinal Fatty Acid-Binding Protein and Drug AbsorptionFigure 1. Chemical-Shift Perturbation Mapping of Ligand Binding to I-FABP
(A–D) Amino acids that displayed significant 13Ca and
13Cb atom chemical-shift changes (>0.6 ppm) upon ligand binding were mapped onto the crys-
tal structure of rat I-FABP. Perturbed residues are colored by using a linear ramp from white to red (minimal to highest perturbation). The molecular
surface of the protein is depicted; the portal region is shown in ribbon representation. The two views are rotated by 120 about the y axis. The bottom
panels show a plot of the 13Ca and
13Cb chemical-shift changes upon ligand binding versus residue number. The >0.6 ppm threshold for a significant
perturbation is shown as a red, horizontal line. The highly affected residues are shown as vertical, green bars. Stars indicate unassigned residues. (A)
Chemical-shift perturbations induced by palmitic acid binding have been mapped onto the crystal structure of holo-palmitic acid-rat I-FABP
(2IFB.pdb). (B–D) The crystal structure of holo-myristate-rat I-FABP (1ICM.pdb) was employed for the drug-docking models; the ligands (B) fenofibric
acid, (C) tolfenamic acid, and (D) clofibric acid are shown in CPK representation in the position of the optimal docking solutions.This is consistent with the general understanding that dif-
fusion across the unstirred water layer (UWL) adjacent to
the membrane surface is typically the rate-limiting step
in the membrane permeation of highly lipophilic molecules
[14, 21, 22]. Thus, the rates of diffusion of these small
molecules across the UWL were high and similar in all
cases [22]. In contrast, the rates of uptake of the less lipo-
philic probes, ibuprofen (log D7.4 = 0.77), propranolol (logChemistry & Biology 14,D7.4 = 0.97), and tolfenamic acid, (log D7.4 = 2.3), were
lower, suggesting that uptake into the membrane was
limited by membrane (as opposed to UWL) permeability.
For the more lipophilic compounds, the initial rate of dis-
appearance from the donor chamber was nonlinear and
markedly higher than the rate of appearance in the accep-
tor chamber. These differences reflect drug accumulation
in the membrane (Figure 2, middle column). Closer453–465, April 2007 ª2007 Elsevier Ltd All rights reserved 457
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retention was, as expected, related to drug lipophilicity
and decreased across the series oleic acidz progester-
one > diazepam > tolfenamic acid > propranolol > ibupro-
fen. Drug concentrations in the membrane appeared to
equilibrate after 3 hr, after which time the rate of disap-
pearance from the donor chamber approximated the
rate of drug appearance in the acceptor chamber, indicat-
ing that conditions of steady-state drug transport had
been attained (data not shown).
The presence of I-FABP in the acceptor chamber did
not affect the kinetics of drug uptake into the membrane.
In contrast, the rate of appearance of drug in the acceptor
chamber was in some cases highly dependent on the
presence of I-FABP. Thus, the transport of oleic acid, tol-
fenamic acid, progesterone, and, to a lesser extent, ibu-
profen was significantly enhanced by the presence of
I-FABP in the acceptor chamber (Table 3). Importantly,
Table 2. Disappearance Kinetics Permeability Values
Measured at pH 7.4 by the PAMPA Method
Donor/Acceptor Buffer/Buffer Buffer/I-FABP
Oleic acid 240 ± 11 240 ± 2.0
Tolfenamic acid 111 ± 25 101 ± 30
Progesterone 240 ± 26 270 ± 51
Ibuprofen 43 ± 6.9 50 ± 6.7
Diazepam 220 ± 10 200 ± 17
Propranolol 100 ± 14 100 ± 7.9
Caffeine 100 ± 3.0 100 ± 4.2
Mannitol NDa NDa
Pe = 10
6 cm$s1. Mean ± SD, n = 3.
a ND, not detected.458 Chemistry & Biology 14, 453–465, April 2007 ª2007 Elseviethe degree of transport enhancement was also reflective
of the relative drug binding affinity to I-FABP (Table 3;
Table S1). For oleic acid and tolfenamic acid, the presence
of I-FABP also reduced drug retention in the membrane
and facilitated improved partitioning into the aqueous
receptor compartment (Figure 2; Table S1). The impact
of I-FABP in enhancing both the rate and extent of mem-
brane transport is best exemplified by tolfenamic acid
(Ki = 2.8 mM), although qualitatively similar events are
evident with the lower-affinity ligands progesterone
(Ki = 20 mM) and ibuprofen (Ki = 58 mM). Consistent with
the very weak binding interaction between I-FABP and
diazepam and the lack of interaction with propranolol,
no significant differences in membrane retention or per-
meability were seen in the presence of I-FABP for these
two probes.
In order to simulate drug permeation from the entero-
cyte cytosol across the basolateral membrane and into
the underlying lamina propria, PAMPA assays were con-
ducted with the inclusion of I-FABP (0.33 mM) in the donor
chamber and HSA (0.66 mM) in the acceptor chamber.
Under these conditions, oleic acid, tolfenamic acid, pro-
gesterone, and diazepam all showed enhanced appear-
ance Pe values when compared to identical conditions
but in the absence of albumin in the acceptor chamber
(Table 3). In each case, the observed enhancement was
dictated by drug lipophilicity and the relative binding affin-
ities of each compound for HSA and I-FABP (Table 3).
Drug binding to HSA promoted transport into the acceptor
chamber, whereas drug binding to I-FABP in the donor
chamber opposed this enhancement. Thus, no significant
differences in transport were observed for the less lipo-
philic compounds ibuprofen and propranolol, and, in the
case of oleic acid, the increase in transport resulting
from HSA binding in the acceptor chamber was attenu-
ated by similarly strong binding to I-FABP in the donor.Table 3. Appearance Kinetics Permeability Values Measured at pH 7.4 by the PAMPA Method
Donor/
Acceptor
Buffer/
Buffer
Buffer/
I-FABP
I-FABP/
Buffer
I-FABP/
HSA
I-FABP Binding
Affinity (Ki, mM)
HSA Binding
Affinity (Ki, mM)
Effective Partition
Coefficient
(log DpH7.4)
Oleic acid 1.2 ± 0.4 650 ± 29a 0.50 ± 0.1 9.2 ± 0.7b 0.056 ± 0.01 0.089 ± 0.01 3.48
Tolfenamic acid 8.1 ± 2.3 25.4 ± 3.2a 3.3 ± 1.4 7.4 ± 2.4b 2.8 ± 0.7 1.1 ± 0.5 2.32
Progesterone 32 ± 2.4 60 ± 5.4a 12 ± 1.3 190 ± 20b 20 ± 4.6 Site 1: 0.020 ± 0.006;
Site 2: 30 ± 3.8
4.04
Ibuprofen 4.0 ± 0.8 6.3 ± 0.8a 3.3 ± 0.3 4.0 ± 0.5 58 ± 8.4 22 ± 4.3 0.77
Diazepam 36 ± 2.0 40 ± 5.5 25 ± 5.2 190 ± 15b 2000 ± 87 73 ± 8.4 2.96
Propranolol 24 ± 2.6 24 ± 1.2 24 ± 0.5 26 ± 0.4 NBc 66 ± 10.2 0.97
Caffeine 2.2 ± 0.1 2.2 ± 0.3 2.4 ± 0.1 2.4 ± 0.3 NBc NBc 0.24
Mannitol NDd NDd NDd NDd NBc NBc 4.67
Pe = 10
6 cm$s1. Mean ± SD, n = 3.
a Significantly larger than Pe obtained in the absence of I-FABP in the acceptor chamber (p < 0.05).
b Significantly larger than Pe obtained in the absence of HSA in the acceptor chamber (p < 0.05).
c NB, no binding detected.
d ND, not detected.r Ltd All rights reserved
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Recent advances in cell and structural biology have re-
sulted in the identification of a wide range of transport
proteins on the apical and basolateral membranes of en-
terocytes and have subsequently shown that these pro-
teins can facilitate vectorial transport processes that
either assist or impede (efflux) drug absorption. While con-
siderable progress has therefore been made in the struc-
tural and functional characterization of transmembrane
drug transporters, the role of cytosolic binding proteins
in drug transport across the cell and intracellular drug
transport to, for example, cytosolic sites of metabolism
or translational signaling remains ill defined. In light of
this, to our knowledge, the current study provides the first
data linking specific structural details of drug binding to
intracellular FA carrier proteins, such as I-FABP, with the
potential impact on drug transport.
Notwithstanding their highly conserved tertiary struc-
tures, iLBPs can be divided into four subfamilies based
on sequence homology and differences in ligand selectiv-
ity and binding geometries [23]. Subfamily I comprises the
cellular retinoid-binding proteins in which a single ligand is
typically bound near the cavity entrance under the double
helix cap domain. The carboxylate of the ligand forms
hydrogen bonds with highly conserved arginine and tyro-
sine residues within the ligand binding cavity. Subfamily II
consists of L-FABP and the ileal bile acid-binding protein
(I-BABP), which have two ligand-binding sites within the
cavity. Both L-FABP and I-BABP are able to bind bulky
ligands on account of their higher backbone flexibility
and larger ligand entrance when compared to other iLBPs.
Subfamily IV contains several different iLBP types, includ-
ing heart, epidermal, and brain FABPs, which generally
bind one FA in a U-shaped conformation. In structures
of this subfamily, the carboxylate group of the FA is com-
plexed by a network of hydrogen bonds with the side
chains of the highly conserved cavity residues Arg106,
Arg126, and Tyr128. I-FABP is the sole member of sub-
family III, which is somewhat different from other iLBP
subfamilies in the manner it binds FA [23]. I-FABP binds
a single FA in an extended and slightly bent conformation
[19, 23, 24]. Different FAs bind to I-FABP in very similar
locations and orientations and differ principally in their in-
teractions with residues located within the dynamic portal.
The binding interactions of I-FABP with its endogenous
ligand (FA) have been widely reported [5–7, 17, 19, 23, 24].
While it has been known for some time that I-FABP is ca-
pable of interacting with non-FA ligands [25], there have
been few studies characterizing its broader binding spec-
ificity. In the present study, we have characterized I-FABP
binding to a range of lipophilic drugs. Detailed examina-
tion of the interaction of a range of compounds with
I-FABP has allowed aspects of the drug binding specificity
of the I-FABP binding cavity to be elucidated. The rank
order of drug affinities observed can be rationalized in
terms of the binding modes suggested by the NMR chem-
ical-shift perturbations and the docking studies. These
data suggest that each of the drugs binds within the cavityChemistry & Biology 14of I-FABP through a network of bonding interactions.
Thus, fenofibric acid and tolfenamic acid appear to bind
in somewhat different orientations—particularly with re-
spect to the location of their carboxylate groups; however,
their overall affinity is similar. In contrast, clofibric acid
binds with its carboxylate group in a similar location to
fenofibric acid and FA, but it is unable to access the hydro-
phobic groove and portal, which presumably contributes
to its lower affinity. None of the drugs completely fill the
binding cavity of I-FABP, suggesting that bulkier and
structurally diverse ligands may be accommodated.
Binding and structural studies with an Arg106-Gln mu-
tant of I-FABP have demonstrated that the ionic interaction
is not essential for FA binding [19, 24]. In these studies,
although FA affinity was reduced 20 fold and the binding
conformation was less well defined, FA was shown to bind
the mutant FABP in a broadly similar conformation to the
native protein [24]. Studies with the naturally occurring
Ala54-Thr mutant human I-FABP have also indicated that
the size of the portal residues appears to influence access
to the binding cavity, although this did not greatly affect
ligand binding affinity or selectivity [6, 7]. Consequently,
there are a number of different binding modes that can
be accommodated within the cavity of I-FABP.
To investigate the possible functional significance of
drug binding to I-FABP, we have examined the impact of
I-FABP on transmembrane drug transport. In the first in-
stance, drug absorption patterns across the apical enter-
ocyte membrane were modeled by the inclusion or exclu-
sion of I-FABP in the acceptor compartment of in vitro
PAMPA assays conducted across a representative phos-
pholipid membrane. In this model, drug movement from
the donor to acceptor compartments reflects (i) diffusion
across the UWL present on the surface of the membrane
in the donor chamber, (ii) partition from the donor com-
partment (as a surrogate for the GI lumen) into the mem-
brane, (iii) diffusion across the membrane, (iv) partition
out of the membrane into the UWL on the acceptor cham-
ber side of the membrane (representing the enterocyte
cytosol), and, finally, (v) diffusion across the UWL into the
bulk (stirred) environment of the acceptor chamber. Any
one of these processes may become rate limiting in terms
of overall transport, and the current data suggest that the
importance of each is dependent on the physicochemical
properties of the drug (primarily lipophilicity), the proper-
ties of the fluids in contact with the membrane (and the
proteins contained therein), and the nature of the binding
interactions that may occur between the drug molecule
and the binding proteins in the acceptor (cf. intracellular)
compartment (Figure 3).
Uptake from the donor chamber into the membrane
(steps i and ii) was essentially a function of drug lipophilic-
ity (Figure 2; Table 2). As such, for the least lipophilic probe
(ibuprofen) uptake was poor and essentially the rate-limit-
ing step in terms of transport. In contrast, membrane up-
take increased for the more lipophilic compounds and for
the most lipophilic (oleic acid, progesterone, diazepam)
was rapid and likely limited only by permeability across
the UWL (step i). Intermediate uptake was evident for, 453–465, April 2007 ª2007 Elsevier Ltd All rights reserved 459
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Intestinal Fatty Acid-Binding Protein and Drug AbsorptionFigure 3. Schematic Representation of Proposed Passive Molecular Transport Mechanisms for a Lipophilic Drug across the
Enterocyte
The passive diffusional uptake of a lipophilic drug from the intestinal lumen across the enterocyte interior is initiated by (1) partitioning into the outer
leaflet of the apical membrane and movement across the bilayer core. (Active uptake or transport mechanisms within the apical membrane are also
present; however, they are omitted for clarity.) Partitioning from the inner leaflet of the apical membrane into the cytosol subsequently occurs where
binding to FABP (2) favors cytoplasmic solubilization. Binding to I-FABP in the cytoplasm is a function of the operational dissociation constant (Kd),
[free drug] and [apo-I-FABP], in the cytosol (3). The high concentration of I-FABP in the enterocyte facilitates binding of lipophilic drugs with moderate
affinities. In the absence of FABP (4), diffusional return to the apical membrane is expected to be favored (5). I-FABP binding allows drug access to
intracellular organelles such as the nucleus (depicted) (6) and transcellular delivery to the basolateral membrane (7). Uptake from the basolateral
membrane into the extracellular space is driven by high-capacity HSA binding (8). The low-capacity paracellular transport route is represented by
green arrows and is predominately responsible for the absorption of hydrophilic molecules with limited membrane affinity. The broken, red arrow
represents the lateral diffusion pathway of the drug within the plasma membrane.drugs with intermediate lipophilicity (tolfenamic acid, pro-
pranolol). Uptake permeability coefficients were identical
regardless of the presence or absence of I-FABP in the
acceptor compartment (Table 2). This is consistent with
the literature, which suggests that passive membrane per-
meability is determined in large part by lipophilicity (al-Chemistry & Biology 14, 4though this concept has been recently refined to include
a realization that the anisotropy of lipid bilayers dictates
that some degree of amphiphilicity is also required to
promote membrane binding [26]).
Transport of the more lipophilic probes into the ac-
ceptor compartment (when the acceptor compartmentFigure 2. Transmembrane Flux of Lipophilic Drugs in the Absence and Presence of I-FABP
(A–F) (A) Oleic acid. (B) Tolfenamic acid. (C) Progesterone. (D) Ibuprofen. (E) Diazepam. (F) Propranolol. First panel: the disappearance kinetics of each
compound measured as a function of time. Data are represented as the mass fraction in the donor chamber at time t (CD[t]) relative to time 0 (CD[0]).
Middle panel: the percentage membrane retention (%R) of each compound in the absence (black bars) and presence (gray bars) of I-FABP in the
acceptor chamber. Third panel: the appearance flux of drug into the acceptor chamber over time in the absence (squares) and presence (triangles)
of 0.33 mM I-FABP in the acceptor chamber. Data are mean (nR 3) ± SE.53–465, April 2007 ª2007 Elsevier Ltd All rights reserved 461
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brane was high (Table S1). Since membrane uptake was
relatively facile for these compounds and UWL permeabil-
ity was essentially identical on both sides of the mem-
brane (and relatively high), the rate-limiting steps to trans-
membrane transport were expected to be either diffusion
across the phospholipid bilayer (step iii) or partitioning out
of the membrane (step iv) into the aqueous environment of
the acceptor chamber. The data presented in the current
studies do not distinguish specifically between diffusion
across the membrane (step iii), the importance of which
in the overall membrane transport of FA remains conten-
tious [27, 28], and dissociation from the membrane into
the receptor buffers (step iv). The current data do, how-
ever, suggest that significant increases in transport are
possible when physiological concentrations of I-FABP are
added to the fluids bathing the acceptor side of a model
membrane. This is reflective of the situation in vivo in
which FA (or lipophilic drugs) within the inner leaflet of
the apical membrane of the enterocyte is accessible to
intracellular drug-binding proteins, and is also consistent
with the suggestion that drug or FA binding to iLBP may
facilitate membrane dissociation. The increase in the rate
and extent of transport in the current studies was, at least
in rank-order terms, reflective of the ligand binding affinity
for I-FABP. Thus, effects were especially noticeable
for oleic acid (Ki = 0.06 mM), but were also clearly demon-
strated with tolfenamic acid (Ki = 2.8 mM), and to a lesser
extent progesterone (Ki = 20 mM). Importantly, the
cytosolic concentration of FABPs in the enterocyte is
0.2–0.4 mM [1, 3, 4], which is far in excess of the total
FA concentration, leaving excess FABP available for bind-
ing to lower-affinity ligands, including drug molecules.
While molecular interactions between drug molecules
and iLBPs clearly favor drug entry into the enterocyte, it
is also apparent that the same interactions may impede
drug transport from the cytosol, into and across the baso-
lateral membrane. To assess this issue, an additional
series of PAMPA studies was conducted, and the data
in Table 3 demonstrate that, in the absence of albumin in
the acceptor chamber, the transmembrane transport of
oleic acid, tolfenamic acid, and progesterone is indeed
impeded by the presence of I-FABP in the donor compart-
ment. However, it is also clear that the presence of albu-
min in the acceptor compartment dramatically enhances
membrane transport, and, again, the degree of enhance-
ment is consistent with drug-protein binding affinity. Sim-
ilar trends were seen for ibuprofen; however, in this case,
the protein-binding response was considerably damped
by the intrinsically low membrane permeability of this
less lipophilic drug. Diazepam permeability was particu-
larly enhanced by the presence of albumin in the acceptor
chamber, a situation reflecting its high affinity for albumin
and relatively poor affinity for I-FABP.
The data therefore suggest that the transport of a num-
ber of lipophilic drugs across the apical membrane of the
enterocyte and into the essentially aqueous environment
of the enterocyte cytosol is, in an analogous fashion to
oleic acid, facilitated by interaction with a cytosolic bind-462 Chemistry & Biology 14, 453–465, April 2007 ª2007 Elseving protein. Numerous experimental and theoretical
studies have shown that the presence of FABP stimulates
FA mobility in artificial systems [10, 29], cell culture models
[30], and perfused rat livers [31]. The current studies
demonstrate that several classes of lipophilic drug mole-
cules bind to I-FABP, and that the presence of I-FABP in
a model membrane system facilitates their transmem-
brane transport.
Within the cytosol, iLBPs have also previously been
shown to facilitate the delivery of endogenous ligands
(FA) to specific intracellular locations, including the endo-
plasmic reticulum (where re-esterification to triglyceride
and subsequent assembly into lipoproteins occurs), and
to the nucleus, where FA regulates the expression of
a number of proteins involved in lipid metabolism, includ-
ing FABP, via binding to nuclear hormone receptors
(NHRs) such as the PPARs [9, 12, 32]. In the latter case,
iLBPs appear to govern the transcriptional activities of
their endogenous ligands by targeting them to cognate
NHRs, which, in turn, effects transcription of the genes as-
sociated with their absorption and metabolism [9, 12, 32].
Previous studies have shown that regulation of numerous
proteins, including the cytochrome P450 enzymes and
efflux transporters such as p-glycoprotein, involved in de-
toxification of drug molecules are also under the control of
NHRs [33]. Together with the current data, this raises the
interesting possibility that iLBPs may also play a role in di-
recting intracellular interactions of drug molecules with
NHRs, thereby affecting transcriptional changes to the
proteins involved with drug detoxification (Figure 3).
Studies to address this latter aspect are ongoing.
SIGNIFICANCE
To our knowledge, this work provides a new level of
understanding of the process of drug absorption and
the possible mechanisms by which drug molecules
are transported across the absorptive cells lining the
small intestine (enterocytes) and are delivered to cyto-
solic sites of metabolism and transcriptional regula-
tion.While there has been considerable recent interest
in the role of membrane-resident transporters in the
movement of drug molecules across the apical and
basolateral membranes of the enterocyte, far less
evidence exists to explain themechanism of transport
of drugs across the cellular cytoplasm. This is espe-
cially true for very poorly water-soluble and highly li-
pophilic drugs in which transport across the essen-
tially aqueous domain of the cellular cytoplasm is
likely to be limiting. It is well known that families of
intracellular binding proteins assist in the movement
and delivery of endogenous lipophilic ligands such
as FAs to intracellular organelles. To this end, the cur-
rent study is the first, to our knowledge, to describe
the specific binding properties of a range of drug
molecules to one of these intracellular carrier proteins
(I-FABP), and to link this structural and binding affinity
data to a functional outcome, namely, drug transport
across a model membrane system.ier Ltd All rights reserved
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Materials
Oleic acid, [1-14C] (60 mCi/mmol), and ibuprofen, R/S-[carboxylate-
14C] (60 mCi/mmol), were purchased from MP Biomedicals
Australia (Seven Hills, N.S.W., Australia). Diazepam, [methyl-3H] (76
Ci/mmol); propranolol, L-[4-3H] (20 Ci/mmol); 14C-D-mannitol, [1-14C]
(56 mCi/mmol); caffeine, [1-methyl-14C] (51.2 mCi/mmol); and proges-
terone, [1,2,6,7-3H(N)] (52 Ci/mmol) were purchased from Perkin-
Elmer Life Sciences (Boston, MA). Isopropyl b-D-thiogalactopyrano-
side (IPTG) was purchased from BioVectra (Prince Edward Island,
Canada). R- and S-flurbiprofen were purchased from Cayman Chem-
ical Company (Ann Arbor, Michigan). All other (nonradiolabelled)
drugs, 1-anilino-8-naphthalene sulfonic acid (ANS), and myristic acid
were obtained from Sigma (Sydney, N.S.W., Australia). The Multi-
Screen Permeability Plate Assembly was purchased from pION, Inc.
(Woburn, MA).
Expression and Purification of Rat I-FABP
Recombinant rat I-FABP protein in the unlabelled or 15N/13C-
isotopically labeled form was expressed and purified as described
previously [11].
Fluorescence Measurements
Drug binding affinity to I-FABP was measured as described previously
[11]. Fluorimetric titrations were performed below the aqueous solubil-
ity and critical micellular concentration limits of the test compounds.
The solubility limits of test compounds in the assay buffer were tested
by UV/Vis spectrophotometry. None of the compounds displayed sig-
nificant absorption in the wavelength region of excitation (400 nm) or
emission (420–600 nm); thus, no corrections for inner filter effects
were applied. ANS binding and displacement assays for drug binding
to human serum albumin (HSA) were as described previously [34]. The
dissociation constant of ANS for HSA in buffer A (20 mM Tris [pH 8.0])
was 2.7 ± 0.4 mM. Data were analyzed as previously described [11]
with GraphPad Prism V4.0 software (GraphPad Software, San Diego,
CA). In accordance with the literature, the binding affinity values for
drug-HSA ANS displacement assays are reported as operational
constants, as the binding stoichiometry of the drug-HSA complexes
is not known [34].
NMR Spectroscopy
NMR experiments were conducted at 22C in 20 mM MES (pH 5.5),
50 mM NaCl (90% H2O:10% D2O) on a Varian UNITY Inova 600 MHz
spectrometer equipped with a pulsed-field gradient triple-resonance
cryoprobe. Standard triple-resonance experiments [35] (and refer-
ences therein) were employed to obtain assignment for I-FABP. Exper-
iments were processed with NMRPipe [36] and were analyzed by using
SPARKY [37]. Chemical-shift perturbations were calculated by using
Equation 1:
Dd=O

Dd13Ca
2
+

Dd13Cb
2
; (1)
where Dd13Ca and Dd
13Cb, respectively, denote the
13Ca and
13Cb
chemical-shift changes between the apo and holo proteins for a partic-
ular residue. A combined chemical-shift change > 0.6 ppm was taken
as significant [38]. For palmitic acid, the resonances of Ala32, Phe62,
and Ser71 were omitted from the analysis, due to the large deviation
of their chemical shifts from average values collated in the BioMagRes-
Bank database. Chemical-shift perturbations were mapped onto crys-
tallographic structures of rat I-FABP by using ProtSkin [39], and figures
were generated with PYMOL [40].
Chemical Synthesis
Fenofibric acid was prepared by alkaline hydrolysis of fenofibrate
under mild conditions as previously described [41].Chemistry & Biology 14, 4Molecular Docking
Drug structures were docked into the rat I-FABP crystal structure
(1ICM) by using FlexX V1.12 as implemented in Sybyl V6.91 (Tripos
Inc., St. Louis, MO).
Chemi-Informatics Calculations
The log P, log D (pH 7.4), and pKa values of the test compounds were
calculated by using Advanced Chemistry Development software
Solaris V4.67 (ACD/Labs, Toronto, Canada).
Parallel Artificial Membrane Permeability Assay
Filter-immobilized artificial membrane techniques were employed for
assessing the membrane transport of drug molecules in the presence
and absence of protein acceptor sinks [14, 21, 42]. The parallel artificial
membrane permeability assay (PAMPA) consists of a ‘‘sandwich’’ as-
sembly formed from a 96-well microfilter acceptor plate (Millipore Mul-
tiscreen, Sydney, N.S.W., Australia) and an indented 96-well filter plate
(pION). Each composite well of the assembly is divided into two cham-
bers, a donor at the bottom and an acceptor at the top, separated by
a 125 mm thick hydrophobic polyvinylidene fluoride (PVDF) microfilter
disc (0.45 mm pore size). The disc of each well is coated with a 2%
(w/v) dodecane solution of 1,2-dioleoyl-sn-glycero-3-phosphocholine
(pION P/N 110669) that forms multilamellar lipid bilayers inside the filter
channels when in contact with an aqueous buffer solution. The donor
and acceptor solutions contained an identical buffer composition
(buffer B, 20 mM Tris [pH 7.4], 50 mM NaCl). The donor buffer solutions
contained 0.009–0.35 mCi radiolabelled test compound, 30 mM unla-
belled compound (including < 1% [v/v] DMSO), and, where indicated,
0.33 mM I-FABP. Sample solutions were filtered before use. Acceptor
solutions contained buffer B, or where indicated 0.66 mM HSA or
0.33 mM I-FABP in buffer B. The acceptor filter plate was placed on
top of the donor plate forming the ‘‘sandwich’’ and incubated for
0.5–7.0 hr in a sealed box under conditions of constant humidity to
minimize evaporation. At the appropriate sampling points, the PAMPA
sandwich was separated, and the radioactivity in both donor and
acceptor compartments was assayed by liquid scintillation counting
of 100 ml samples from each chamber. The concentration of drug in
each chamber was determined from the specific radioactivity of
each compound. Tolfenamic acid transport assays were performed
with unlabelled compound. Sample concentrations were assayed by
UV/Vis spectrometry (Tolfenamic acid, lmax = 286 nm).
The rate of solute uptake into the membrane was calculated by
fitting the disappearance kinetics data to a single-phase exponential
decay equation (Equation 2) [42]:
CDðtÞ=CDð0Þ= ðCD½0  CDssÞ  expðK  tÞ+CDss; (2)
where CD(t) and CD(0) are the concentrations of compound in the
donor chamber at time t and time 0 (mol/l), respectively. CDss is the
postequilibrium (3–7 hr) steady-state concentration of drug in the do-
nor chamber. K is the first-order uptake rate constant (mol/l/s). The
permeability coefficient (Pe) describing uptake into the membrane
was calculated from K by using Equation 3:
Pe

106 cm=s

=K3 ðVD=AÞ; (3)
where VD is the volume in the donor chamber (0.2 cm3), and A is the
effective surface area of the filter disc available for diffusion (0.18 cm2).
The actual filter surface area, 0.24 cm2, was corrected for an apparent
membrane porosity of 76% [21] to give an effective filter surface area
of 0.18 cm2.
Pe describing donor-to-acceptor transmembrane transport was also
calculated by using data describing the appearance of radiolabelled
compound in the acceptor chamber over time. Permeability coeffi-
cients were generated by using Equation 4 and data taken over the
period of steady-state transport (which generally occurred over the
period of 3–7 hr):
Pe

106 cm=s

=dCA=dt3 ðVA=A3CD½0Þ; (4)53–465, April 2007 ª2007 Elsevier Ltd All rights reserved 463
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acceptor chamber over the steady-state transport period of 3–7 hr (i.e.,
the flux into the acceptor chamber, mol/l/s). CD(0) is the initial concen-
tration of compound in the donor chamber at the start of the steady-
state transport period (mol/l), VA is the volume in the acceptor chamber
(0.2 cm3), and A is the effective surface area of the filter disc available
for diffusion (0.18 cm2). All experiments were performed in triplicate,
and data are reported as mean ± SD.
Mass balance calculations (Equation 5) were used to quantify the
proportion of material retained in the phospholipid membrane barrier
(%R) (Equation 6), where CA(t) and CD(t) are the concentration of the
compound in the acceptor and donor chambers, respectively, at
time (t).
Mass balance= ðCA½t+CD½tÞ=CDð0Þ; (5)
%R= ð1  Mass balanceÞ3 100: (6)
Statistically significant differences between data sets were deter-
mined by one-way ANOVA, followed by Tukey’s test for multiple com-
parisons at a significance level of a = 0.05. All statistical analysis was
performed by using GraphPad Prism V4.0 software.
Supplemental Data
Supplemental data include additional analysis of the membrane reten-
tion data for the PAMPA drug transport model, chemical structures of
the drugs examined for I-FABP binding affinity, and 1H-15N HSQC
spectra of drug-I-FABP complexes are available online at http://
www.chembiol.com/cgi/content/full/14/4/453/DC1/.
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